HPV-RELATED SQUAMOUS CELL CARCINOMA
Clinical trials for HPV-RELATED SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HPV-RELATED SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HPV-RELATED SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental immune therapy aims to tackle HPV cancers before standard care
Disease control Recruiting nowThis study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…
Matched conditions: HPV-RELATED SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Supercharged immune cells take on HPV cancers
Disease control Recruiting nowThis study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…
Matched conditions: HPV-RELATED SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Christian Hinrichs • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Could less radiation be just as effective for HPV throat cancer?
Disease control Recruiting nowThis study tests whether a personalized, lower dose of radiation (guided by a special PET scan) works as well as the standard dose for people with HPV-positive throat cancer. About 291 participants will receive either the lower or standard radiation dose, along with standard chem…
Matched conditions: HPV-RELATED SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can immunotherapy let doctors dial down cancer treatment without sacrificing cures?
Disease control Recruiting nowThis phase II trial is testing whether giving the immunotherapy drug cemiplimab (sometimes with chemotherapy) before standard treatment can shrink tumors enough to allow less intense local therapy, such as reduced radiation or surgery. The goal is to maintain high cure rates whil…
Matched conditions: HPV-RELATED SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC